Ratings Health Italia S.p.A.

Equities

Real-time Borsa Italiana Other stock markets 11:20:11 2024-05-31 am EDT			5-day change	1st Jan Change
119.5 ^EUR	+2.14%		-2.45%	-1.24%

Mar. 19	Futures passive; BoJ abandons negative rates.	AN
Mar. 18	Milan at parity; De Nora on bottom after accounts	AN

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

The stock, which is currently worth 2024 to 0.57 times its sales, is clearly overvalued in comparison with peers.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

	1st Jan change	Capi.	ESG Refinitiv
HEALTH ITALIA S.P.A.	-1.24%	23.72M	-
HAPVIDA PARTICIPAÇÕES E INVESTIMENTOS S.A.	-9.44%	5.98B	C
ODONTOPREV S.A.	-3.61%	1.21B	B

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality